Marco Schito, PhD is Executive Director of C-Path’s CURE Drug Repurposing Collaboratory and an Adjunct Professor at the University of Arizona, James E. Rogers College of Law. His work aims to discover potentially safe and effective repurposed therapies for diseases with high unmet medical needs by capturing and sharing global, real-world clinical data. Prior to joining C-Path, Dr. Schito was a Senior Scientific Officer at the Division of AIDS, NIH where he wrote and managed point-of-care diagnostic contracts for developing HIV viral load assays in low-resource settings, stood up a fully characterized HIV global viral diversity panel program, and launched a research initiative to standardize the measurement of mucosal immune responses in HIV clinical trials. During his intramural tenure at the National Cancer Institute, Dr Schito led the in vivo modelling of anti-retroviral zinc finger inhibitors, characterized TCR transgenic murine models, and the immune characterization of mice deficient in p53 phosphatases (PPM1D). Over the past decade, he established a data knowledgebase to enable the use of Next Generation Sequencing platforms to identify efficacious tuberculosis drug regimens quickly and accurately. This platform is now being used by the World Health Organization for its global genomic drug surveillance program. Dr Schito received his PhD from the Ontario Veterinary College at the University of Guelph, Canada in immuno-parasitology.
